Autoinjectors are the medical devices used to deliver a fixed dose of particular drug to patients. Most of these autoinjectors are pre-filled spring-loaded syringes, which consists of a hypodermic needle and a push button in order to deliver the dose. They are relatively very easy to use and designed for safe administration of the drugs. It is technically advanced and overcome any risks associated with the conventional syringes and traditionally used self-injection devices.
The Asia-Pacific Autoinjectors Market was worth USD 0.44 billion in 2018 and estimated to be growing at a CAGR of 18.2%, to reach USD 1.01 billion by 2023.
There are many varieties of autoinjectors available in the market which would meet the requirement of patients in the therapeutic areas. They are mainly intended for the self-medication of the patients at home and also reduce needle phobia. Autoinjectors are mainly used in the treatment of the anaphylaxis, rheumatoid arthritis, multiple sclerosis, and others. The Auto injectors market is showcasing a substantial CAGR during the forecast period with the rising prevalence of anaphylaxis attack.
The major factors driving for the Asia-Pacific Autoinjectors Market are technology advancement and innovation in the drug delivery systems, growing adoption of auto-injectors, rising prevalence of anaphylaxis incidences, diabetes and cancer, simplifying self-medication and improving patient compliance, many advantages like safety, comfort and the accuracy, favourable government policies and high investments by the private companies. However, high price, lack of patient awareness towards self-medication, injuries associated with auto-injectors and stringent regulations are hindering the market growth.
The Asia-Pacific Autoinjectors market is segmented on the basis of product, usability, manufacturing design, technology, application and end-user. On the basis of product type, the market is segmented into fillable autoinjectors and prefilled autoinjectors. Based on the usability, the market is segmented into disposable autoinjectors and reusable autoinjectors. Depending on the Manufacturing Design, the market is categorized into standardized autoinjectors and customized autoinjectors. On the basis of technology, the market is segmented into automated autoinjectors and manual autoinjectors. Based on the application, the market is segmented into anaphylaxis, multiple sclerosis, and rheumatoid arthritis. On the basis of Distribution Channels, the market is segmented into hospitals, retail, online pharmacies and others. Anaphylaxis segment is the largest segment in terms of revenue while Prefilled auto-injectors segment in product type is anticipated to have the highest growth rate. The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Asia-Pacific is growing at the fastest rate due to the rising population, increase in chronic diseases and emerging economies like China and India.
Major autoinjector manufacturing companies dominating the market are Mylan N.V., Pfizer, Inc., Bayer AG, Becton, Dickinson and Company, Novartis AG, Biogen Idec, Inc., Janssen Asia-Pacific Services, LLC, Sanofi, Unilife Corporation and Eli Lilly and Company.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Fillable Autoinjectors
5.1.3 Prefilled Autoinjectors
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Usability
5.2.1 Introduction
5.2.2 Disposable Autoinjectors
5.2.3 Reusable Autoinjectors
5.2.4 Y-o-Y Growth Analysis, By Usability
5.2.5 Market Attractiveness Analysis, By Usability
5.2.6 Market Share Analysis, By Usability
5.3 Manufacturing Design
5.3.1 Introduction
5.3.2 Standardized Autoinjectors
5.3.3 Customized Autoinjectors
5.3.4 Y-o-Y Growth Analysis, By Manufacturing Design
5.3.5 Market Attractiveness Analysis, By Manufacturing Design
5.3.6 Market Share Analysis, By Manufacturing Design
5.4 Technology
5.4.1 Introduction
5.4.2 Automated Autoinjectors
5.4.3 Manual Autoinjectors
5.4.4 Y-o-Y Growth Analysis, By Technology
5.4.5 Market Attractiveness Analysis, By Technology
5.4.6 Market Share Analysis, By Technology
5.5 Application
5.5.1 Introduction
5.5.2 Anaphylaxis
5.5.3 Multiple Sclerosis
5.5.4 Rheumatoid Arthritis
5.5.5 Y-o-Y Growth Analysis, By Application
5.5.6 Market Attractiveness Analysis, By Application
5.5.7 Market Share Analysis, By Application
5.6 Distribution Channels
5.6.1 Introduction
5.6.2 Hospitals
5.6.3 Retail
5.6.4 Online Pharmacies
5.6.5 Others
5.6.6 Y-o-Y Growth Analysis, By Distribution Channels
5.6.7 Market Attractiveness Analysis, By Distribution Channels
5.6.8 Market Share Analysis, By Distribution Channels
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Usability
6.1.3.4 By Manufacturing Design
6.1.3.5 By Technology
6.1.3.6 By Application
6.1.3.7 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Usability
6.1.4.4 By Manufacturing Design
6.1.4.5 By Technology
6.1.4.6 By Application
6.1.4.7 By Distribution Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Usability
6.1.5.4 By Manufacturing Design
6.1.5.5 By Technology
6.1.5.6 By Application
6.1.5.7 By Distribution Channels
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Mylan N.V.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer, Inc.,
8.3 Bayer AG
8.4 Becton, Dickinson and Company
8.5 Novartis AG
8.6 Biogen Idec, Inc.,
8.7 Janssen Global Services
8.8 Sanofi
8.9 Eli Lilly and Company
8.10 Unilife Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
